JP4043220B2 - Lipolysis promoter and slimming method - Google Patents
Lipolysis promoter and slimming method Download PDFInfo
- Publication number
- JP4043220B2 JP4043220B2 JP2001355677A JP2001355677A JP4043220B2 JP 4043220 B2 JP4043220 B2 JP 4043220B2 JP 2001355677 A JP2001355677 A JP 2001355677A JP 2001355677 A JP2001355677 A JP 2001355677A JP 4043220 B2 JP4043220 B2 JP 4043220B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- lipolysis
- acid residue
- slimming
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Confectionery (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Description
【0001】
【発明の属する技術分野】
本発明は、全身もしくは局所の脂肪組織の減少を促進することによる肥満体質の改善、又は同組織の増大を防止することによる肥満の抑制もしくは防止に有効な脂肪分解促進剤及び皮膚外用剤並びに飲食品組成物に関する。
【0002】
【従来の技術及び発明が解決しようとする課題】
体内の脂肪は、消費エネルギーに対し、摂取エネルギーの過剰分が、白色脂肪細胞の中性脂肪として蓄積して生じる物である。体脂肪としての蓄積が大きい肥満は、美容上好ましくないばかりでなく、動脈硬化等の様々な疾病を引き起こす。最近、過食、運動不足、ストレス等による肥満が増加しているが、反面、特に女性は外見上からもスリムな引き締まった体を切望する傾向にある。また、皮下脂肪等の蓄積は、健康上も好ましくなく、皮下脂肪等の減少、もしくは蓄積の防止が重要な問題となっている。
【0003】
肥満防止作用を有する物質としてトウガラシ等に含まれるカプサイシン類は血中のアルブミンと結合し、副腎の代謝を促進するホルモンを分泌し、肝臓や脂肪細胞に作用してエネルギー代謝を活発化することが知られている(岩井和夫及び中谷延二著、香辛料成分の食品機能、97頁、1989年)。しかしながら、カプサイシン類は強い刺激を有しているために、その用途や使用量を限定される問題があった。
【0004】
一度蓄積した脂肪細胞を無くすのは難しく、脂肪細胞をなるべく小さくすることが早道であり、そのためには脂肪中の油滴を分解することが必要であると考えた。油滴は蛋白質と同じように酵素(ホスホリパーゼC)によって分解されるが、油滴は水をはじくリン脂質の膜に覆われているために油滴周辺の小包体という水の固まりの中にいる酵素は近づくことができない。一方、運動することで交感神経を活発にすることにより脂肪分解ホルモンが分泌される。このホルモンはリン脂質の膜を取り除き、酵素と油滴の親和性を高めることで脂肪分解を促進すると考えられている。そこで、このホルモンと同様に油滴と酵素の親和性を高める働きをもつ物質を見つけることが必要であると考えられていた。
【0005】
本発明者等は、ラズベリーケトンやジンゲロン及びその誘導体が脂肪組織に蓄積された脂肪の分解を促進し、肥満の抑制、又は肥満体質の改善に有効であることを見出している(特開2000−169325号公報)。しかしながら、ラズベリーケトンやジンゲロンは特有の芳香を有しているために配合量や汎用性の点において満足できるものではなかった。
【0006】
そこで、より汎用性に優れ、かつ皮下脂肪等を抑制又は減少させる満足な効果を有する脂肪分解促進剤及び痩身用化粧料並びに飲食品組成物が望まれていた。
【0007】
したがって、本発明は、汎用性に優れ、かつ全身もしくは局所の脂肪組織の減少を促進することによる肥満体質の改善、又は同組織の増大を防止することによる肥満の抑制もしくは防止に有効な脂肪分解促進剤及び痩身用皮膚化粧料並びに飲食品組成物を提供することを目的とするものである。
【0008】
【課題を解決するための手段】
上記目的を達成するために、本発明者等は脂肪細胞に作用し脂肪分解を促進する作用を有し、かつ特異な芳香や味を有しない物質について鋭意研究した結果、下記一般式(1)で示される化合物が脂肪組織に蓄積された脂肪の分解を促進し、肥満の抑制、又は肥満体質の改善に有効であることを見出し、本発明を完成した。
【0009】
【化4】
【0010】
(但し、式中、Rは水素原子であるか、炭素数1〜12の飽和又は不飽和である直鎖又は分岐鎖の炭化水素基であるか、グルコース残基、キナ酸残基又はシキミ酸残基である。そして、波線部は、波線部は単結合を示す。)
【0011】
即ち、本発明は、上記一般式(1)で示される化合物からなる脂肪分解促進剤、該化合物を含有する皮膚外用剤並びに痩身用飲食品組成物にある。
【0012】
【発明の実施の形態】
以下、本発明の実施の形態に関し、詳説する。本発明に用いられる前記一般式(1)で示される化合物としては、例えば、ジヒドロコーヒー酸、クロロゲン酸、イソクロロゲン酸、ネオクロロゲン酸、プソイドクロロゲン酸のジヒドロ化合物(水素添加物)、ジヒドロコーヒー酸グルコシド、ジヒドロコーヒー酸アルキル(1〜12)エステル等が挙げられ、これらの中でもコーヒー酸、クロロゲン酸、イソクロロゲン酸、ネオクロロゲン酸、プソイドクロロゲン酸のジヒドロ化合物が好ましく、特にジヒドロコーヒー酸、ジヒドロクロロゲン酸が効果の面より好ましい。
【0013】
本発明に用いられるコーヒー酸は、コーヒー豆等多くの植物に含有され、その誘導体であるコーヒー酸メチルはキク科のテンニンギク、コーヒー酸プレニルはプロポリス、配糖体である1−カフェオイル グルコシドはナス科のシロバナヨウシュチョウセンアサガオ、キナ酸とのエステル体であるクロロゲン酸類はコーヒー豆、サツマイモや南天等に含まれることが知られている。クロロゲン酸は優れた抗酸化作用を有することやビタミンCの安定性を高める効果を有していること等から食品分野において様々な応用が検討されている(特開昭58−138347号公報、特開平6−9603号公報)。また、クロロゲン酸又はその誘導体を配合することによる美白、皮膚老化防止、毛髪保護用化粧料等も提案されているが(特開平8−26967号公報、特開平10−29908号公報)、これらのコーヒー酸誘導体が脂肪分解促進作用を有していることは何ら記載も示唆もされていない。
【0014】
一方、ジヒドロコーヒー酸はアカザ科のテーブルビート等に含まれていることが知られている。またジヒドロコーヒー酸誘導体は先のコーヒー酸誘導体を定法により水素添加することにより得ることができる。クロロゲン酸のカフェオイル基を還元することにより得られるジヒドロクロロゲン酸が肝臓のグルコース−6−燐酸塩変換酵素の阻害剤として報告されているが(ドラッグ デリヴァリー リサーチ 第44巻第1号34−40頁1998)。また、本発明者等はジヒドロクロロゲン酸がクロロゲン酸に比較して安全性が高く(感作性を有しない)ことを確認するとともに優れた抗酸化作用を有することを確認し皮膚化粧料への応用を既に提案しているが(特開2000−336022号公報)、ジヒドロコーヒー酸誘導体が脂肪分解促進作用を有していることは今回はじめて判明したことである。
【0015】
本発明で用いるコーヒー酸及びその誘導体は、コーヒー抽出物等、本発明でいうところのコーヒー酸誘導体を多量に含む天然抽出物をそのまま用いることもできる。またジヒドロコーヒー酸及びその誘導体は、先に記載のコーヒー酸及びその誘導体を多量に含む天然抽出物をそのままパラジウム黒等を用いて不飽和結合を還元することにより得たものを用いることもできる。これらの中で、不飽和結合を還元した水素添加コーヒーエキスが効果の面より好ましい。
【0016】
前記一般式(1)で表される化合物は、脂肪分解促進剤として、一種又は二種以上を併用することができる。また、痩身用皮膚化粧料等の皮膚外用剤並びに飲食品組成物に用いる場合、皮膚外用剤や飲食品組成物の形態によっても種々異なり一概に規定できるものではないが、配合量は、例えば、該組成物中に0.001〜20質量%配合するのが好ましい。0.001重量%未満では本発明の効果を奏しない場合があり、20重量%を越えて配合しても、配合量に見合った効果が得られない場合がある。
【0017】
本発明の脂肪分解促進剤を痩身用皮膚化粧料等の皮膚外用剤に用いる場合には、通常の皮膚化粧料において使用される、油分、顔料、界面活性剤、保湿剤、紫外線吸収剤、抗炎症剤、殺菌剤、防腐剤、色素等の他に、ブトパミン、イソプロテレノール等のβアドレナリン作用興奮剤、ヨヒンビン、エルゴトキシン等のα2アドレナリン作用抑制剤、テオフィリン、カフェイン等のキサンチン誘導体、ミルリノン、アムリノン等のビピリジン誘導体等、肥満の抑制又は防止作用を有するラズベリーケトン、ジンゲロン、3,4−ジヒドロキシフェニルー2−ブタノン、ヒドロキシチロソールやシネフリン等の公知物質等を配合することができる。
【0018】
本発明の脂肪分解促進剤を痩身用飲食品組成物に用いる場合には、通常の飲食品組成物において使用される糖類、香料、乳化剤、乳製品、蛋白質、安定剤、着色料、酸味料、油脂、穀類、卵類、ガムベース、カフェイン等のキサンチン誘導体、ハイドロキシクエン酸、肥満の抑制又は防止作用を有するカプサイシン、ラズベリーケトン、ジンゲロン、3,4−ジヒドロキシフェニル−2−ブタノンやシネフリン、ヒドロキシチロソール等の公知物質等を配合することができる。
【0019】
本発明の脂肪分解促進剤は、例えば、食品、経口投与薬、皮膚化粧料等に配合することができ、剤型は特に限定されるものではなく痩身用皮膚化粧料等の皮膚外用剤の場合には、皮膚塗布用、浴用、洗浄用等のクリーム、乳液、ジェル、スティック、シート、パップ、粉末、液体、顆粒等、飲食品組成物の場合にはチューインガム、チョコレート、キャンディ、グミゼリー、飲料、スープ、アイスクリーム、麺類、ベーカリー食品等に配合することができる。
【0020】
【実施例】
以下、実施例を挙げて本発明をさらに詳細に説明するが、本発明は、これらによって限定されるものではない。また、実施例に示す%は、特に記載のない限り質量%を意味する。
【0021】
<ジヒドロ3−カフェオイルキナ酸合成例>
クロロゲン酸1.0gをエタノール50mLに溶かし、この溶液にパラジウムカーボン(5%パラジウム)50mgを加えて、水素雰囲気下(常圧)、室温で15時間激しく攪拌した。セライトを用いてろ過した後、ろ液を減圧下で濃縮し、本発明で用いるジヒドロクロロゲン酸1.0gを得た。
13C−NMR(溶媒:重メタノール、内部標準:テトラメチルシラン);δ=31.4,37.4,38.3,38.9,71.5,72.0,73.7,76.3,116.4,116.5,120.6,133.7,144.6,146.2,174.4,177.0
【0022】
[脂肪分解試験法]
ロッドベルの方法〔Rodbell,M.,J.Biol.Chem.,239,375(1964)〕により、ウィスター系雄性ラット(体重150〜200g)の副睾丸脂肪組織からコラゲナーゼ溶液を用いて遊離脂肪細胞を調製した。被験物濃度を所定量となるよう調製した牛血清アルブミン及びノルエピネフリン(最終濃度0.05μg/mL)を含むハンクス緩衝液中に上記細胞を加え、37℃にて1時間反応した。遊離した脂肪酸を抽出し、銅試薬及び発色試薬により脂肪酸量を定量した。
【0023】
脂肪分解促進率(%)=[A/B]×100
A:被験物添加時の脂肪酸量
B:コントロール(被験物無添加)の脂肪酸量
【0024】
実施例1〜3、比較例1、2
各種脂肪分解促進剤について、上記の脂肪分解試験にて評価した結果を以下に示す。
【0025】
【0026】
実施例1〜3の脂肪分解促進剤は、脂肪分解促進率が比較例1、2に比べはるかに高く脂肪分解促進作用が高いことが明らかにされた。
【0027】
実施例4、比較例3
上記実施例1〜3とは、別に、同様の方法で脂肪分解試験を行った。尚、用いた水素添加コーヒー酸は、クロロゲン酸30%含有するコーヒーエキスを還元したものである。
【0028】
実施例5〜6、比較例4〜5(ジェル状痩身用皮膚化粧料)
以下に示す組成で、常法によりA、B各成分を個別に混合溶解後、B成分をA成分に添加し攪拌することにより、ジェル状痩身用皮膚化粧料を調製した。
【0029】
【0030】
上記ジェル状痩身用皮膚化粧料を20代で体脂肪率35%以上の女性25名(パネル)にの腹部及び大腿部に2gを一日2回、3週間連用塗布してもらった後に痩身効果についてのアンケート結果、実施例4及び5を用いたパネルは腹部等が引き締まったと回答した者が比較例3、4と比してはるかに多かった。
【0031】
実施例7、比較例6,7(チューインガム)
下記組成のチューインガムに有効成分を各々配合し、上記同様のパネルに毎日1日5枚のチューインガム(15g/枚)を1ヶ月摂取させ、体脂肪率が元の体脂肪率よりも5%以上低下した場合を体脂肪減少者として評価した。
*1 ガルシニアエキス:
インターヘルス社製「シトリマックスHCA−500−F」(ヒドロキシクエン酸(HCA)47.5質量%含有)
【0032】
実施例8(錠菓)
下記組成で錠菓を調製した。
組成
ソルビトール 82.9
ショ糖脂肪酸エステル 4
ラズベリー香料 0.1
ガルシニアエキス *1 3
コーヒー由来クロロゲン酸 10
【0033】
【発明の効果】
以上のとおり、本発明は、全身あるいは局所の脂肪組織を減少させ、肥満の抑制又は防止、肥満体質の改善に有効な脂肪分解促進剤、及び該脂肪分解促進剤を用いることを特徴とする痩身方法を提供できることは明らかである。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a lipolysis promoter, a skin external preparation, and a food and drink that are effective in improving obesity by promoting reduction of systemic or local adipose tissue, or suppressing or preventing obesity by preventing the increase of the tissue. Product composition.
[0002]
[Prior art and problems to be solved by the invention]
Fat in the body is a product of excess energy consumed compared to energy consumed, accumulated as neutral fat in white fat cells. Obesity with a large accumulation as body fat is not only cosmetically unfavorable, but also causes various diseases such as arteriosclerosis. Recently, obesity due to overeating, lack of exercise, stress, and the like has increased, but on the other hand, women tend to crave a slim, firm body in terms of appearance. In addition, accumulation of subcutaneous fat and the like is not preferable from the viewpoint of health, and it is an important problem to reduce or prevent the accumulation of subcutaneous fat and the like.
[0003]
Capsaicins contained in capsicum and the like as substances with anti-obesity action bind to albumin in blood, secrete hormones that promote adrenal metabolism, and act on liver and fat cells to activate energy metabolism. Known (Kazuo Iwai and Nobuji Nakatani, Food function of spice ingredients, page 97, 1989). However, since capsaicins have strong irritation, there is a problem that their use and use amount are limited.
[0004]
It was difficult to eliminate the fat cells that had accumulated once, and it was the fastest way to make the fat cells as small as possible, and for that purpose, it was necessary to break down the oil droplets in the fat. Oil droplets are broken down by enzymes (phospholipase C) in the same way as proteins. However, oil droplets are covered with a phospholipid membrane that repels water, so they are in a mass of water called a parcel around the oil droplets. Enzymes cannot be approached. On the other hand, lipolytic hormone is secreted by activating the sympathetic nerve by exercising. This hormone is thought to promote lipolysis by removing the phospholipid membrane and increasing the affinity between the enzyme and oil droplets. Therefore, it was thought that it was necessary to find a substance having the function of enhancing the affinity between oil droplets and enzymes as well as this hormone.
[0005]
The present inventors have found that raspberry ketone, gingerone and derivatives thereof promote the degradation of fat accumulated in adipose tissue and are effective in suppressing obesity or improving obesity constitution (Japanese Patent Laid-Open No. 2000-169325). Issue gazette). However, since raspberry ketone and gingerone have a unique fragrance, they are not satisfactory in terms of blending amount and versatility.
[0006]
Therefore, there has been a demand for a lipolysis accelerator, a slimming cosmetic, and a food and beverage composition that are more versatile and have a satisfactory effect of suppressing or reducing subcutaneous fat and the like.
[0007]
Therefore, the present invention is highly versatile and effective in improving obesity by promoting the reduction of systemic or local adipose tissue, or effective in suppressing or preventing obesity by preventing the increase of the same tissue. An object of the present invention is to provide an accelerator, a slimming skin cosmetic, and a food and beverage composition.
[0008]
[Means for Solving the Problems]
In order to achieve the above object, the present inventors have conducted extensive research on substances that act on fat cells to promote lipolysis and have no specific aroma or taste. As a result, the following general formula (1) It was found that the compound represented by the formula promotes the degradation of fat accumulated in adipose tissue and is effective in suppressing obesity or improving the obesity constitution, thereby completing the present invention.
[0009]
[Formula 4]
[0010]
(Wherein, R is a hydrogen atom, a saturated or unsaturated linear or branched hydrocarbon group having 1 to 12 carbon atoms, a glucose residue, a quinic acid residue or a shikimic acid. (The wavy line indicates a single bond .)
[0011]
That is, this invention exists in the lipolysis promoter which consists of a compound shown by the said General formula (1), the skin external preparation containing this compound, and the food-drinks composition for slimming.
[0012]
DETAILED DESCRIPTION OF THE INVENTION
Hereinafter, embodiments of the present invention will be described in detail. Examples of the compound represented by the general formula (1) used in the present invention include dihydrocaffeic acid, chlorogenic acid, isochlorogenic acid, neochlorogenic acid, pseudochlorogenic acid dihydro compound (hydrogenated product), and dihydro coffee. Acid glucoside, dihydrocaffeic acid alkyl (1-12) ester, and the like. Among them , dihydro compounds of caffeic acid, chlorogenic acid, isochlorogenic acid, neochlorogenic acid, pseudochlorogenic acid are preferable, particularly dihydrocaffeic acid, Dihydrochlorogenic acid is preferred from the viewpoint of effect.
[0013]
Caffeic acid used in the present invention is contained in many plants such as coffee beans, and its derivative methyl caffeate is asteraceae of asteraceae, prenyl caffeate is propolis, and glycoside 1-caffeoyl glucoside is eggplant. It is known that chlorogenic acids, which are an ester body with the genus Shirobana dwarf morning glory, and quinic acid, are contained in coffee beans, sweet potatoes, southern sky, and the like. Various applications have been studied in the food field because chlorogenic acid has an excellent antioxidant action and has an effect of enhancing the stability of vitamin C (Japanese Patent Laid-Open No. 58-138347, special feature). Kaihei 6-9603). In addition, whitening, prevention of skin aging, and cosmetics for protecting hair by blending chlorogenic acid or its derivatives have been proposed (JP-A-8-26967, JP-A-10-29908). There is no description or suggestion that caffeic acid derivatives have a lipolysis promoting action.
[0014]
On the other hand, it is known that dihydrocaffeic acid is contained in table beets of the family Rabbitaceae. The dihydrocaffeic acid derivative can be obtained by hydrogenating the previous caffeic acid derivative by a conventional method. Dihydrochlorogenic acid obtained by reducing the caffeoyl group of chlorogenic acid has been reported as an inhibitor of hepatic glucose-6-phosphate converting enzyme (Drug Delivery Research Vol. 44, No. 1, pages 34-40). 1998). In addition, the present inventors confirmed that dihydrochlorogenic acid is higher in safety than chlorogenic acid (does not have a sensitizing property) and has an excellent antioxidant effect, and thus applied to skin cosmetics. Although application has already been proposed (Japanese Patent Application Laid-Open No. 2000-336022), it has been found for the first time that a dihydrocaffeic acid derivative has an action of promoting lipolysis.
[0015]
As the caffeic acid and its derivative used in the present invention, a natural extract containing a large amount of the caffeic acid derivative referred to in the present invention, such as a coffee extract, can be used as it is. Dihydrocaffeic acid and derivatives thereof may be those obtained by reducing unsaturated bonds of the natural extract containing a large amount of caffeic acid and derivatives thereof as described above using palladium black or the like as it is. Among these, a hydrogenated coffee extract obtained by reducing unsaturated bonds is preferable from the viewpoint of effects.
[0016]
The compound represented by the general formula (1) can be used alone or in combination of two or more as a lipolysis accelerator. In addition, when used for skin external preparations such as slimming skin cosmetics and food / beverage product compositions, the amount of blending is, for example, It is preferable to mix | blend 0.001-20 mass% in this composition. If the amount is less than 0.001% by weight, the effect of the present invention may not be achieved. Even if the amount exceeds 20% by weight, the effect corresponding to the amount may not be obtained.
[0017]
When the lipolysis promoter of the present invention is used in a skin external preparation such as a slimming skin cosmetic, oils, pigments, surfactants, moisturizers, ultraviolet absorbers, anti-oxidants, and the like used in normal skin cosmetics. In addition to inflammatory agents, bactericides, preservatives, pigments, etc., β-adrenergic stimulants such as butopamine and isoproterenol, α2-adrenergic inhibitors such as yohimbine and ergotoxin, xanthine derivatives such as theophylline and caffeine, milrinone In addition, known substances such as raspberry ketone, zingerone, 3,4-dihydroxyphenyl-2-butanone, hydroxytyrosol and synephrine, which have an action to suppress or prevent obesity, such as bipyridine derivatives such as amrinone, can be blended.
[0018]
When the lipolysis promoter of the present invention is used in a slimming food / beverage product composition, sugars, flavors, emulsifiers, dairy products, proteins, stabilizers, colorants, acidulants used in normal food / beverage product compositions, Fats and oils, cereals, eggs, gum bases, xanthine derivatives such as caffeine, hydroxycitric acid, capsaicin having an action to suppress or prevent obesity, raspberry ketone, gingerone, 3,4-dihydroxyphenyl-2-butanone, synephrine, hydroxytyrosol A known substance such as can be blended.
[0019]
The lipolysis promoter of the present invention can be blended in, for example, foods, orally administered drugs, skin cosmetics, etc., and the dosage form is not particularly limited, and in the case of a skin external preparation such as slimming skin cosmetics For skin application, bathing, washing, etc., cream, emulsion, gel, stick, sheet, pap, powder, liquid, granule, etc., in the case of food and beverage composition, chewing gum, chocolate, candy, gummy jelly, beverage, It can be blended in soups, ice creams, noodles, bakery foods and the like.
[0020]
【Example】
EXAMPLES Hereinafter, although an Example is given and this invention is demonstrated further in detail, this invention is not limited by these. Moreover,% shown in an Example means the mass% unless there is particular description.
[0021]
<Example of dihydro-3-caffeoylquinic acid synthesis>
1.0 g of chlorogenic acid was dissolved in 50 mL of ethanol, 50 mg of palladium carbon (5% palladium) was added to this solution, and the mixture was vigorously stirred at room temperature for 15 hours in a hydrogen atmosphere (normal pressure). After filtration using Celite, the filtrate was concentrated under reduced pressure to obtain 1.0 g of dihydrochlorogenic acid used in the present invention.
13 C-NMR (solvent: deuterated methanol, internal standard: tetramethylsilane); δ = 31.4, 37.4, 38.3, 38.9, 71.5, 72.0, 73.7, 76. 3, 116.4, 116.5, 120.6, 133.7, 144.6, 146.2, 174.4, 177.0
[0022]
[Lipolysis test method]
Rodbell method [Rodbell, M .; , J .; Biol. Chem. , 239, 375 (1964)], free adipocytes were prepared from a testicular adipose tissue of Wistar male rats (body weight 150 to 200 g) using a collagenase solution. The cells were added to Hank's buffer containing bovine serum albumin and norepinephrine (final concentration 0.05 μg / mL) prepared so that the test substance concentration was a predetermined amount, and reacted at 37 ° C. for 1 hour. The liberated fatty acid was extracted, and the amount of fatty acid was quantified with a copper reagent and a coloring reagent.
[0023]
Lipolysis promotion rate (%) = [A / B] × 100
A: Fatty acid amount at the time of test substance addition B: Fatty acid amount of control (no test substance added)
Examples 1 to 3, Comparative Examples 1 and 2
About the various lipolysis promoter, the result evaluated in said lipolysis test is shown below.
[0025]
[0026]
It was clarified that the lipolysis promoters of Examples 1 to 3 have a much higher lipolysis promotion rate than Comparative Examples 1 and 2, and a high lipolysis promoting action.
[0027]
Example 4, Comparative Example 3
Separately from Examples 1 to 3, a lipolysis test was performed in the same manner. The hydrogenated caffeic acid used was obtained by reducing a coffee extract containing 30% chlorogenic acid.
[0028]
Examples 5 to 6, Comparative Examples 4 to 5 (gel-like slimming skin cosmetics)
A gel-like slimming skin cosmetic was prepared by mixing and dissolving each of the A and B components individually in a conventional manner and adding the B component to the A component and stirring.
[0029]
[0030]
Slimming after applying the above gel-like slimming skin cosmetics to the abdomen and thighs of 25 women (panels) who have a body fat percentage of 35% or more in their twenties twice a day for 3 weeks. As a result of the questionnaire about the effect, the panel using Examples 4 and 5 had far more people who answered that the abdomen etc. were tightened compared with Comparative Examples 3 and 4.
[0031]
Example 7, Comparative Examples 6 and 7 (chewing gum)
Each of the chewing gums with the following composition is blended with active ingredients, and the same panel as above is fed 5 chewing gums (15 g / sheet) daily for 1 month. The body fat percentage is 5% lower than the original body fat percentage. The case was evaluated as a person with reduced body fat.
* 1 Garcinia extract:
“CITRIMAX HCA-500-F” manufactured by InterHealth (containing 47.5% by mass of hydroxycitric acid (HCA))
[0032]
Example 8 (tablet confectionery)
Tablet confectionery was prepared with the following composition.
Composition Sorbitol 82.9
Sucrose fatty acid ester 4
Raspberry flavor 0.1
Garcinia extract * 1 3
Coffee-derived chlorogenic acid 10
[0033]
【The invention's effect】
As described above, the present invention uses a lipolysis accelerator effective for reducing systemic or local adipose tissue, suppressing or preventing obesity, and improving obesity constitution, and a slimming body using the lipolysis accelerator It is clear that a method can be provided.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001355677A JP4043220B2 (en) | 2001-11-21 | 2001-11-21 | Lipolysis promoter and slimming method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001355677A JP4043220B2 (en) | 2001-11-21 | 2001-11-21 | Lipolysis promoter and slimming method |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2003160483A JP2003160483A (en) | 2003-06-03 |
JP4043220B2 true JP4043220B2 (en) | 2008-02-06 |
Family
ID=19167346
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001355677A Expired - Lifetime JP4043220B2 (en) | 2001-11-21 | 2001-11-21 | Lipolysis promoter and slimming method |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4043220B2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1674106B1 (en) | 2003-10-06 | 2011-09-21 | Oryza Oil & Fat Chemical Co., Ltd | Dietetic composition |
JP2006335758A (en) * | 2003-10-06 | 2006-12-14 | Oriza Yuka Kk | Composition for diet |
JP5357372B2 (en) * | 2004-03-17 | 2013-12-04 | 花王株式会社 | Skin symptom improving agent |
EP1604643A1 (en) * | 2004-06-03 | 2005-12-14 | Cognis France, S.A.S. | Cosmetic use of derivatives of 3-Phenylpropionic acid |
JP4741206B2 (en) * | 2004-07-12 | 2011-08-03 | 日本甜菜製糖株式会社 | Composition for suppressing or reducing serum cholesterol elevation |
FR2896694A1 (en) * | 2006-01-30 | 2007-08-03 | Genfit S A | USE OF 15-LIPOXYGENASE INHIBITORS IN THE TREATMENT OF METABOLIC SYNDROME |
JP4990534B2 (en) * | 2006-02-02 | 2012-08-01 | ポーラ化成工業株式会社 | Caffeoylquinic acid derivative and composition for suppressing plasminogen activator inhibitor comprising the same as an active ingredient |
JP2008120730A (en) * | 2006-11-13 | 2008-05-29 | Kao Corp | Gel-shaped cosmetic |
JP5783784B2 (en) * | 2011-04-25 | 2015-09-24 | オリザ油化株式会社 | Nitric oxide production inhibitor |
JP2014070056A (en) * | 2012-09-28 | 2014-04-21 | Oriza Yuka Kk | Fat accumulation inhibitor |
JP2018513106A (en) * | 2015-03-03 | 2018-05-24 | ネステク ソシエテ アノニム | Compounds for use in promoting energy consumption |
-
2001
- 2001-11-21 JP JP2001355677A patent/JP4043220B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP2003160483A (en) | 2003-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4819171B2 (en) | Wrinkle improving agent, lipolysis accelerator, skin external composition, and food and beverage composition | |
JP5118292B2 (en) | Lipolysis accelerator | |
JP4887499B2 (en) | Active oxygen scavenger and moisturizer containing wild watermelon extract | |
JP4043220B2 (en) | Lipolysis promoter and slimming method | |
JP4136143B2 (en) | Lipolysis accelerator and slimming skin cosmetics | |
JP2010053122A (en) | Lipid synthesis inhibitor | |
JP4456321B2 (en) | Lipase inhibitor | |
JP2009161475A (en) | Insulin-like growth factor-1 production promoter | |
JP2004331579A (en) | Production promoter of corium matrix | |
JP4325908B2 (en) | Lipolysis accelerator, skin external preparation and food and drink using the same | |
JP2000026228A (en) | Collagenase inhibitor, moisturizer, and cosmetic or food containing the same | |
EP1753391A1 (en) | Use of furan alkyls for a cellulite cosmetic treatment | |
JP4630052B2 (en) | Lipolysis accelerator, composition for external use on skin and food and beverage composition | |
JP4421847B2 (en) | Lipolysis accelerator | |
JP2001172150A (en) | Composition for oral cavity and medicinal composition for external use | |
JP4542765B2 (en) | Enzyme inhibitor | |
JP2003146870A (en) | Lipid degradation promoter and method of slimming body | |
JP2004161678A (en) | Anti-inflammatory agent and cyclic amp phosphodiesterase inhibitor | |
JP4053743B2 (en) | Immunomodulator | |
JP3766026B2 (en) | Lipolysis accelerating food | |
JP2004284990A (en) | Skin cosmetic and oral bleaching ingredient | |
JP5442687B2 (en) | Lipolysis accelerator | |
KR20170080084A (en) | Composition for improving skin conditions comprising nepodin | |
KR20170080069A (en) | Composition for improving skin conditions comprising esculentoside A | |
KR20170078102A (en) | Composition for improving skin conditions comprising demethylwedelolactone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20040805 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20040806 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20060328 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070410 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070608 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070724 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070921 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20071113 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20071113 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4043220 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101122 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111122 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121122 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121122 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131122 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |